High-Throughput Screen for the Chemical Inhibitors of Antiapoptotic Bcl-2 Family Proteins by Multiplex Flow Cytometry

Computational Chemistry Group, Romanian Academy Institute of Chemistry, Timisoara, Romania.
Assay and Drug Development Technologies (Impact Factor: 1.53). 05/2011; 9(5):465-74. DOI: 10.1089/adt.2010.0363
Source: PubMed

ABSTRACT The human Bcl-2 family includes six antiapoptotic members (Bcl-2, Bcl-B, Bcl-W, Bcl-X(L), Bfl-1, and Mcl-1) and many proapoptotic members, wherein a balance between the two determines cell life or death in many physiological and disease contexts. Elevated expression of various antiapoptotic Bcl-2 members is commonly observed in cancers, and chemical inhibitors of these proteins have been shown to promote apoptosis of malignant cells in culture, in animal models, and in human clinical trials. All six antiapoptotic members bind a helix from the proapoptotic family member Bim, thus quenching Bim's apoptotic signal. Here, we describe the use of a multiplex, high-throughput flow cytometry assay for the discovery of small molecule modulators that disrupt the interaction between the antiapoptotic members of the Bcl-2 family and Bim. The six antiapoptotic Bcl-2 family members were expressed as glutathione-S-transferase fusion proteins and bound individually to six glutathione bead sets, with each set having a different intensity of red fluorescence. A fluorescein-conjugated Bcl-2 homology region 3 (BH3) peptide from Bim was employed as a universal ligand. Flow cytometry measured the amount of green peptide bound to each bead set in a given well, with inhibitory compounds resulting in a decrease of green fluorescence on one or more bead set(s). Hits and cheminformatically selected analogs were retested in a dose-response series, resulting in three "active" compounds for Bcl-B. These three compounds were validated by fluorescence polarization and isothermal titration calorimetry. We discuss some of the lessons learned about screening a chemical library provided by the National Institutes of Health Small Molecule Repository (∼195,000 compounds) using high-throughput flow cytometry.

Download full-text


Available from: Cristian Bologa, Sep 29, 2015
22 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This probe report describes the identification and development of an inhibitor of Bcl-B, a member of the Bcl-2 family. The Bcl-2 family plays a prominent role in apoptosis. Bcl-2 is over-expressed in some cancers, allowing cells to continue proliferating. Thus, small molecule inhibitors of the anti-apoptotic Bcl-2 family members with their apoptotic partners would be useful for enhancing cancer chemotherapy. We developed a multiplexed bead-based flow cytometry high-throughput assay based on the disruption of the binding of a fluorescently labeled-BH3 peptide of Bim to the six anti-apoptotic Bcl-2 family members: Bcl-XL, Bcl-W, Bcl-B, Bfl-1, and Mcl-1 and Bcl-2 (the eponymous founding member of the Bcl-2 family). Using this assay, we screened each of 200,000 compounds in the NIH Molecular Libraries Small Molecule Repository (MLSMR) simultaneously (in multiplexed format) against all six Bcl-2 family members for potential regulators of these crucial peptide-protein interactions. We were able to develop a potent (368 nM IC50) inhibitor of the interaction of the Bim peptide with Bcl-B that was at least 127-fold selective over the Bim-Bcl-XL interaction. It was also shown to be selective against the other family members (Bcl-W, Bcl-2, Bfl-1, Mcl-1).
    Probe Reports from the NIH Molecular Libraries Program, National Center for Biotechnology Information (US).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Academia and small business research units are poised to play an increasing role in drug discovery, with drug repurposing as one of the major areas of activity. Here we summarize project status for a number of drugs or classes of drugs: raltegravir, cyclobenzaprine, benzbromarone, mometasone furoate, astemizole, R-naproxen, ketorolac, tolfenamic acid, phenothiazines, methylergonovine maleate and beta-adrenergic receptor drugs, respectively. Based on this multi-year, multi-project experience we discuss strengths and weaknesses of academic-based drug repurposing research. Translational, target and disease foci are strategic advantages fostered by close proximity and frequent interactions between basic and clinical scientists, which often result in discovering new modes of action for approved drugs. On the other hand, lack of integration with pharmaceutical sciences and toxicology, lack of appropriate intellectual coverage and issues related to dosing and safety may lead to significant drawbacks. The development of a more streamlined regulatory process world-wide, and the development of pre-competitive knowledge transfer systems such as a global healthcare database focused on regulatory and scientific information for drugs world-wide, are among the ideas proposed to improve the process of academic drug discovery and repurposing, and to overcome the "valley of death" by bridging basic to clinical sciences.
    Drug Discovery Today Therapeutic Strategies 12/2011; 8(3-4):61-69. DOI:10.1016/j.ddstr.2011.10.002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Flow cytometry specializes in high-content measurements of cells and particles in suspension. Having long excelled in analytical throughput of single cells and particles, only recently with the advent of HyperCyt sampling technology, flow cytometry's multiexperiment throughput has begun to approach the point of practicality for efficiently analyzing hundreds-of-thousands of samples, the realm of high-throughput screening (HTS). To extend performance and automation compatibility, we built a HyperCyt-linked Cluster Cytometer platform, a network of flow cytometers for analyzing samples displayed in high-density, 1,536-well plate format. To assess the performance, we used cell- and microsphere-based HTS assays that had been well characterized in the previous studies. Experiments addressed important technical issues: challenges of small wells (assay volumes 10 μL or less, reagent mixing, cell and particle suspension), detecting and correcting for differences in performance of individual flow cytometers, and the ability to reanalyze a plate in the event of problems encountered during the primary analysis. Boosting sample throughput an additional fourfold, this platform is uniquely positioned to synergize with expanding suspension array and cell barcoding technologies in which as many as 100 experiments are performed in a single well or sample. As high-performance flow cytometers shrink in cost and size, cluster cytometry promises to become a practical, productive approach for HTS, and other large-scale investigations of biological complexity.
    Cytometry Part A 05/2012; 81(5):419-29. DOI:10.1002/cyto.a.22039 · 2.93 Impact Factor
Show more